Publications
2020
. Pre-clinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. ESMO Virtual Congress 2020. (Poster ID #11P).
Read More > ESMO Virtual Congress 2020 Poster. Pre-clinical development of the second-generation N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. American Association for Cancer Research Virtual Annual Meeting II 2020. (Abstract ID #1953).
Read More > 2020 AACR Virtual Annual Meeting II Poster. The preclinical characterization and development of EPI-7386, an N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. [Poster Session]. American Urology Association Annual Conference, Washington, DC, United States.
Read More > 2020 American Urology Association Annual Conference Poster. IND Candidate EPI-7386 as an N-terminal Domain Androgen Receptor Inhibitor in Development for the Treatment of Prostate Cancer. American Society of Clinical Oncology Genitourinary Cancers Symposium 2020. (Abstract ID #142).
Read More > 2020 Genitourinary Cancers Symposium Poster
2019
. Treatment of castrated resistant prostate cancer, with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. (Abstract ID B117).
Read More > AACR-NCI-EORTC Poster